On July 30, 2009, BioMarin Pharmaceutical, Inc. (the Company) announced financial results for the second quarter ended June 30, 2009. The
Companys press release issued on July 30, 2009 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

In its press
release, the Company included net income for the quarter and six months ended June 30, 2009, the quarter and six months ended June 30, 2008 and the year ended December 31, 2008 and an estimate of net income for the year ending
December 31, 2009, each not determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP net income for the second quarter of 2008 and 2009 excluded the non-cash stock compensation expense and
certain nonrecurring material items. The non-GAAP net income for the six months ended June 30, 2009 and the six months ended June 30, 2008 excluded the non-cash stock compensation expense, certain nonrecurring material items and the tax
effect of the adjustments. The anticipated non-GAAP net income for the year ending December 31, 2009 and actual results for the year ended December 31, 2008 excluded the non-cash stock compensation expense for 2008, managements
estimate of the non-cash stock compensation expense for 2009, certain other nonrecurring material items and the tax effect of the adjustments for 2008 and 2009. Reconciliations for such non-GAAP financial measures to the comparable GAAP financial
measures are included in the press release attached hereto as Exhibit 99.1.

The Company believes that this non-GAAP information is useful to investors,
taken in conjunction with the Companys GAAP information because it provides additional information regarding the performance of the Companys core ongoing business, Naglazyme, Kuvan and Aldurazyme and development of its pipeline. By
providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the Company believes that the additional information enhances investors overall understanding of the
Companys business and prospects for the future. Further, the Company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.

On November 1, 2007, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter and nine months ended
September 30, 2007. The Companys press release issued on November 1, 2007 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01.

Financial Statements and Exhibits.

(a)

Financial Statements of Business Acquired.

Not
Applicable.

(b)

Pro Forma Financial Information.

Not Applicable.

(c)

Shell Company Transactions.

Not Applicable.

(d)

Exhibits.

Exhibit 99.1 Press Release of the Company
dated November 1, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.